NCT04589845 2026-04-02Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform StudyHoffmann-La RochePhase 2 Active not recruiting920 enrolled 2 FDA
NCT04250155 2026-02-24An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid TumorsGenentech, Inc.Phase 1 Active not recruiting195 enrolled